DOCSLIB.ORG

MAGNESIUM CITRATE NONAHYDRATE Magnesii Citras

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
MAGNESIUM CITRATE NONAHYDRATE Magnesii Citras Magnesium citrate nonahydrate EUROPEAN PHARMACOPOEIA 8.0 thanthatofastandardpreparedatthesametimeandinthe Oxalates: maximum 280 ppm. same manner using 4 mL of a 50 mg/L solution of oxalic Dissolve 0.50 g in a mixture of 3 mL of hydrochloric acid R and acid R. 4mLofwater R and add 1 g of activated zinc R.Allowtostand Sulfates (2.4.13): maximum 0.2percent. for 5 min. Transfer the liquid to a tube containing 0.25 mL of Dilute 3.0 mL of solution S to 15 mL with distilled water R. a 10 g/L solution of phenylhydrazine hydrochloride R.Heat Calcium to boiling. Cool rapidly, transfer to a graduated cylinder and (2.4.3): maximum 0.2 percent. add an equal volume of hydrochloric acid R and 0.25 mL of To a mixture of 2 mL of solution S and 8 mL of distilled potassium ferricyanide solution R.Shakeandallowtostandfor water R, add about 0.2 mL of ammonia R and dilute to 15 mL 30 min. Any pink colour in the solution is not more intense with distilled water R. than that of a standard prepared at the same time and in the Iron (2.4.9): maximum 100 ppm. same manner using 4 mL of a 50 mg/L solution of oxalic Dilute 4.0 mL of solution S to 10 mL with distilled water R. acid R. Sulfates Heavy metals (2.4.8): maximum 10 ppm. (2.4.13): maximum 0.2percent. Dissolve 5.0 g in 15 mL of dilute hydrochloric acid R with Dilute 3.0 mL of solution S to 15 mL with distilled water R. heating. Adjust to pH 3.5 with ammonia R and dilute to Calcium (2.4.3): maximum 0.2 percent. 50 mL with distilled water R. 12 mL of the solution complies To a mixture of 2 mL of solution S and 8 mL of distilled with test A. Prepare the reference solution using lead standard water R,addabout0.2mLofammonia R and dilute to 15 mL solution (1 ppm Pb) R. with distilled water R. Loss on drying (2.2.32): 29.0 per centto 36.0 per cent, Iron (2.4.9): maximum 100 ppm. determined on 1.000 g by drying in an oven at 180 ± 10 °C Dilute 4.0 mL of solution S to 10 mL with distilled water R. for 5 h. Heavy metals (2.4.8): maximum 10 ppm. ASSAY Dissolve 5.0 g in 15 mL of dilute hydrochloric acid R with Dissolve 0.200 g in 5 mL of dilute hydrochloric acid R with heating. Adjust to pH 3.5 with ammonia R and dilute to heating. Cool and add 50 mL of water R.AdjusttopH7.0 50 mL with distilled water R. 12 mL of the solution complies with ammonia R. Carry out the complexometric titration of with test A. Prepare the reference solution using lead standard magnesium (2.5.11). solution (1 ppm Pb) R. 1mLof0.1 M sodium edetate is equivalent to 2.431 mg of Mg. Loss on drying (2.2.32): 24.0 to 28.0 per cent, determined on 1.000 g by drying in an oven at 180 ± 10 °C for 5 h. 01/2010:2402 ASSAY MAGNESIUM CITRATE Dissolve 0.200 g in 5 mL of dilute hydrochloric acid R with heating. Cool and add 50 mL of water R.AdjusttopH7.0 NONAHYDRATE with ammonia R. Carry out the complexometric titration of magnesium (2.5.11). Magnesii citras nonahydricus 1mLof0.1 M sodium edetate is equivalent to 2.431 mg of Mg. 04/2008:2161 MAGNESIUM GLUCONATE Mg3(C6H5O7)2,9H2O Mr 613 [153531-96-5] Magnesii gluconas DEFINITION Trimagnesium bis(2-hydroxypropane-1,2,3-tricarboxylate) nonahydrate. Content: 15.0 per cent to 16.5 per cent of Mg (dried substance). CHARACTERS Appearance: white or almost white, fine powder. C12H22MgO14,xH2O Mr 414.6 (anhydrous substance) Solubility: sparingly soluble in water, practically insoluble in DEFINITION ethanol (96 per cent). It dissolves in dilute hydrochloric acid. Anhydrous or hydrated magnesium D-gluconate. IDENTIFICATION Content: 98.0 per cent to 102.0 per cent (anhydrous substance). A. It gives the reaction of citrates (2.3.1). CHARACTERS B. It gives the reaction of magnesium (2.3.1). Appearance: white or almost white, amorphous, hygroscopic, C. Loss on drying (see Tests). crystalline or granular powder. TESTS Solubility: freely soluble in water, slightly soluble in ethanol (96 per cent), very slightly soluble in methylene chloride. Solution S. Dissolve 2.5 g in 15 mL of dilute hydrochloric acid R with heating. Cool and dilute to 100 mL with distilled IDENTIFICATION water R. A. Thin-layer chromatography (2.2.27). Appearance of solution. Solution S is clear (2.2.1)and Test solution.Dissolve20mgofthesubstancetobe not more intensely coloured than reference solution BY6 examined in 1 mL of water R. (2.2.2, Method II). Reference solution.Dissolve20mgofcalcium gluconate CRS pH (2.2.3): 6.0 to8.5. in 1 mL of water R, heating if necessary in a water-bath Disperse 5.0 g in carbon dioxide-free water R and dilute to at 60 °C. 100 mL with the same solvent. Centrifuge and measure the Plate: TLC silica gel plate R (5-40 μm) [or TLC silica gel pH of the clear supernatant. plate R (2-10 μm)]. 2674 See the information section on general monographs (cover pages) EUROPEAN PHARMACOPOEIA 8.0 Magnesium glycerophosphate Mobile phase: concentrated ammonia R, ethyl acetate R, DEFINITION water R, ethanol (96 per cent) R (10:10:30:50 V/V/V/V). Mixture, in variable proportions, of magnesium Application:1μL. salts of (RS)-2,3-dihydroxypropyl phosphate and Development:over3/4oftheplate. 2-hydroxy-1-(hydroxymethyl)ethyl phosphate, which may be Drying: at 100-105 °C for 20 min, then allow to cool to hydrated. room temperature. Content: 11.0 per cent to 12.5 per cent of Mg (dried substance). Detection: spray with a solution containing 25 g/L of CHARACTERS ammonium molybdate R and 10 g/L of cerium sulfate R in dilute sulfuric acid R,thenheatat100-105°Cforabout Appearance: white or almost white powder, hygroscopic. 10 min. Solubility: practically insoluble in ethanol (96 per cent). It Results: the principal spot in the chromatogram obtained dissolves in dilute solutions of acids. with the test solution is similar in position, colour and size IDENTIFICATION to the principal spot in the chromatogram obtained with the reference solution. A. Mix 1 g with 1 g of potassium hydrogen sulfate R in atesttubefittedwithaglasstube.Heatstronglyand B. To 10 mL of solution S (see Tests) add 3 mL of ammonium direct the white vapour towards a piece of filter paper chloride solution R. A slight opalescence may be observed. impregnated with a freshly prepared 10 g/L solution of Add 10 mL of disodium hydrogen phosphate solution R.A sodium nitroprusside R.Thefilterpaperdevelopsablue white precipitate is formed that does not dissolve upon the colour in contact with piperidine R. addition of 2 mL of dilute ammonia R1. B. Ignite 0.1 g in a crucible. Take up the residue with 5 mL of TESTS nitric acid R and heat on a water-bath for 1 min. Filter. The Solution S.Dissolve1.0ginwater R and dilute to 50 mL with filtrate gives reaction (b) of phosphates (2.3.1). the same solvent. C. It gives the reaction of magnesium (2.3.1). Appearance of solution . Solution S is clear (2.2.1) and not TESTS more intensely coloured than reference solution Y (2.2.2, 7 Solution S Method II). .Dissolve2.5gincarbon dioxide-free water R Sucrose and reducing sugars prepared from distilled water R and dilute to 50 mL with the .Dissolve0.5ginamixtureof same solvent. 2mLofhydrochloric acid R1 and 10 mL of water R. Boil for Appearance of solution 5 min, allow to cool, add 10 mL of sodium carbonate solution R . Solution S is not more opalescent andallowtostandfor10min.Diluteto25mLwithwater R than reference suspension III (2.2.1). and filter. To 5 mL of the filtrate add 2 mL of cupri-tartaric Acidity.Dissolve1.0gin100mLofcarbon dioxide-free solution R and boil for 1 min. Allow to stand for 2 min. No water R.Add0.1mLofphenolphthalein solution R.Notmore red precipitate is formed. than 1.5 mL of 0.1 M sodium hydroxide is required to change Chlorides (2.4.4): maximum 500 ppm. the colour of the indicator. Dilute 5 mL of solution S to 15 mL with water R. Glycerol and ethanol (96 per cent)-soluble substances: Sulfates (2.4.13): maximum 500 ppm. maximum 1.5 per cent. Dissolve2.0ginamixtureof10mLofacetic acid R and 90 mL Shake 1.0 g with 25 mL of ethanol (96 per cent) R for 2 min. of distilled water R. Filter and wash the residue with 5 mL of ethanol (96 per cent) R. Combine the filtrate and the washings, evaporate to Heavy metals (2.4.8): maximum 10 ppm. dryness on a water-bath and dry the residue at 70 °C for 1 h. Dissolve 2.0 g in 20 mL of water R.12mLofthesolution The residue weighs a maximum of 15 mg. complies with test A. Prepare the reference solution using lead Chlorides (2.4.4): maximum 0.15 per cent. standard solution (1 ppm Pb) R. Water Dissolve 1.0 g in water R and dilute to 100 mL with the same (2.5.32): maximum 12.0 per cent, determined on 80 mg. solvent. Dilute 3.5 mL of this solution to 15 mL with water R. Microbial contamination . Total viable aerobic count (2.6.12) Phosphates (2.4.11): maximum0.5percent.
Load more

Recommended publications
  • Appendix a Common Abbreviations Used in Medication
    UNIVERSITY OF AMSTERDAM MASTERS THESIS Impact of Medication Grouping on Fall Risk Prediction in Elders: A Retrospective Analysis of MIMIC-III Critical Care Database Student: SRP Mentor: Noman Dormosh Dr. Martijn C. Schut Student No. 11412682 – SRP Tutor: Prof. dr. Ameen Abu-Hanna SRP Address: Amsterdam University Medical Center - Location AMC Department Medical Informatics Meibergdreef 9, 1105 AZ Amsterdam Practice teaching period: November 2018 - June 2019 A thesis submitted in fulfillment of the requirements for the degree of Master of Medical Informatics iii Abstract Background: Falls are the leading cause of injury in elderly patients. Risk factors for falls in- cluding among others history of falls, old age, and female gender. Research studies have also linked certain medications with an increased risk of fall in what is called fall-risk-increasing drugs (FRIDs), such as psychotropics and cardiovascular drugs. However, there is a lack of consistency in the definitions of FRIDs between the studies and many studies did not use any systematic classification for medications. Objective: The aim of this study was to investigate the effect of grouping medications at different levels of granularity of a medication classification system on the performance of fall risk prediction models. Methods: This is a retrospective analysis of the MIMIC-III cohort database. We created seven prediction models including demographic, comorbidity and medication variables. Medica- tions were grouped using the anatomical therapeutic chemical classification system (ATC) starting from the most specific scope of medications and moving up to the more generic groups: one model used individual medications (ATC level 5), four models used medication grouping at levels one, two, three and four of the ATC and one model did not include med- ications.
    [Show full text]
  • Chlorthalidone Is Superior to Potassium Citrate in Reducing Calcium Phosphate Stones and Increasing Bone Quality in Hypercalciuric Stone-Forming Rats
    BASIC RESEARCH www.jasn.org Chlorthalidone Is Superior to Potassium Citrate in Reducing Calcium Phosphate Stones and Increasing Bone Quality in Hypercalciuric Stone-Forming Rats Nancy S. Krieger,1 John R. Asplin,2 Ignacio Granja,2 Felix M. Ramos,1 Courtney Flotteron,1 Luojing Chen,1 Tong Tong Wu,3 Marc D. Grynpas,4 and David A. Bushinsky1 1Division of Nephrology, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York; 2Litholink Corporation, Laboratory Corporation of America Holdings, Chicago, Illinois; 3Department of Biostatistics and Computational Biology, University of Rochester School of Medicine, Rochester, New York; and 4Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada ABSTRACT Background The pathophysiology of genetic hypercalciuric stone-forming rats parallels that of human idiopathic hypercalciuria. In this model, all animals form calcium phosphate stones. We previously found that chlorthalidone, but not potassium citrate, decreased stone formation in these rats. Methods To test whether chlorthalidone and potassium citrate combined would reduce calcium phos- phate stone formation more than either medication alone, four groups of rats were fed a fixed amount of a normal calcium and phosphorus diet, supplemented with potassium chloride (as control), potassium citrate, chlorthalidone (with potassium chloride to equalize potassium intake), or potassium citrate plus chlorthalidone. We measured urine every 6 weeks and assessed stone formation and bone quality at 18 weeks. Results Potassium citrate reduced urine calcium compared with controls, chlorthalidone reduced it fur- ther, and potassium citrate plus chlorthalidone reduced it even more. Chlorthalidone increased urine citrate and potassium citrate increased it even more; the combination did not increase it further.
    [Show full text]
  • Potassium-Magnesium Citrate Is an Effective Prophylaxis Against Recurrent Calcium Oxalate Nephrolithiasis
    0022-5347/97/1586-2069$03.00/0 JOURNAL OF UROLOGY Vol. 158,2069-2073, December 1997 Copyright Q 1997 by AMERICANUROLOGICAL ASS~CIATION, INC. Printed in U.S.A. POTASSIUM-MAGNESIUM CITRATE IS AN EFFECTIVE PROPHYLAXIS AGAINST RECURRENT CALCIUM OXALATE NEPHROLITHIASIS BRUCE ETTINGER,* CHARLES Y. C. PAK, JOHN T. CITRON, CARL THOMAS, BEVERLEY ADAMS-HIJET AND ARLINE VANGESSEL From the Diuision of Research, Kaiser Permanente Medical Care Program, Oakland, California, the Department of Mineral Metabolism, Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, Department of Medicine, Kaiser Permanente Medical Center, Walnut Creek, California, Department of Urology, Kaiser Permanente Medical Center, San Francisco, California, and Kaiser Foundation Research Institute, Kaiser Foundation Hospitals, Oakland, California ABSTRACT Purpose: We examined the efficacy of potassium-magnesium citrate in preventing recurrent calcium oxalate kidney calculi. Materials and Methods: We conducted a prospective double-blind study of 64 patients who were randomly assigned to receive placebo or potassium-magnesium citrate (42 mEq. potassium, 21 mEq. magnesium, and 63 mEq. citrate) daily for up to 3 years. Results. New calculi formed in 63.6%of subjects receiving placebo and in 12.9%of subjects receiving potassium-magnesiumcitrate. When compared with placebo, the relative risk of treat- ment failure for potassium-magnesium citrate was 0.16 (95%confidence interval 0.05 to 0.46). potassium-magnesium citrate had a statistically significant effect (relative risk 0.10,95%confi- dence interval 0.03 to 0.36) even after adjustment for possible confounders, including age, pretreatment calculous event rate and urinary biochemical abnormalities.
    [Show full text]
  • The Importance of Minerals in the Long Term Health of Humans Philip H
    The Importance of Minerals in the Long Term Health of Humans Philip H. Merrell, PhD Technical Market Manager, Jost Chemical Co. Calcium 20 Ca 40.078 Copper 29 Cu 63.546 Iron Magnesium 26 12 Fe Mg 55.845 24.305 Manganese Zinc 25 30 Mn Zn 55.938 65.380 Table of Contents Introduction, Discussion and General Information ..................................1 Calcium ......................................................................................................3 Copper .......................................................................................................7 Iron ...........................................................................................................10 Magnesium ..............................................................................................13 Manganese ..............................................................................................16 Zinc ..........................................................................................................19 Introduction Daily intakes of several minerals are necessary for the continued basic functioning of the human body. The minerals, Calcium (Ca), Iron (Fe), Copper (Cu), Magnesium (Mg), Manganese (Mn), and Zinc (Zn) are known to be necessary for proper function and growth of the many systems in the human body and thus contribute to the overall health of the individual. There are several other trace minerals requirements. Minimum (and in some cases maximum) daily amounts for each of these minerals have been established by the Institute of
    [Show full text]
  • Some Drugs Are Excluded from Medicare Part D, but Are Covered by Your Medicaid Benefits Under the Healthpartners® MSHO Plan (HMO)
    Some drugs are excluded from Medicare Part D, but are covered by your Medicaid benefits under the HealthPartners® MSHO Plan (HMO). These drugs include some over‐the‐counter (OTC) items, vitamins, and cough and cold medicines. If covered, these drugs will have no copay and will not count toward your total drug cost. For questions, please call Member Services at 952‐967‐7029 or 1‐888‐820‐4285. TTY members should call 952‐883‐6060 or 1‐800‐443‐0156. From October 1 through February 14, we take calls from 8 a.m. to 8 p.m., seven days a week. You’ll speak with a representative. From February 15 to September 30, call us 8 a.m. to 8 p.m. Monday through Friday to speak with a representative. On Saturdays, Sundays and holidays, you can leave a message and we’ll get back to you within one business day. Drug Description Strength 3 DAY VAGINAL 4% 5‐HYDROXYTRYPTOPHAN 50 MG ABSORBASE ACETAMINOPHEN 500 MG ACETAMINOPHEN 120MG ACETAMINOPHEN 325 MG ACETAMINOPHEN 650MG ACETAMINOPHEN 80 MG ACETAMINOPHEN 650 MG ACETAMINOPHEN 160 MG/5ML ACETAMINOPHEN 500 MG/5ML ACETAMINOPHEN 160 MG/5ML ACETAMINOPHEN 500MG/15ML ACETAMINOPHEN 100 MG/ML ACETAMINOPHEN 500 MG ACETAMINOPHEN 325 MG ACETAMINOPHEN 500 MG ACETAMINOPHEN 80 MG ACETAMINOPHEN 100.00% ACETAMINOPHEN 80 MG ACETAMINOPHEN 160 MG ACETAMINOPHEN 80MG/0.8ML ACETAMINOPHEN‐BUTALBITAL 50MG‐325MG ACNE CLEANSING PADS 2% ACNE TREATMENT,EXTRA STRENGTH 10% ACT ANTI‐CAVITY MOUTH RINSE 0.05% Updated 12/01/2012 ACTICAL ACTIDOSE‐AQUA 50G/240ML ACTIDOSE‐AQUA 15G/72ML ACTIDOSE‐AQUA 25G/120ML ACTIVATED CHARCOAL 25 G ADEKS 7.5 MG
    [Show full text]
  • Colonoscopy Instructions Using Miralax and Gatorade, with Magnesium Citrate
    Procedure Locations: The Vancouver Clinic Ambulatory Surgery Center 700 NE 87th Ave Suite 320 Vancouver, WA 98664 Legacy Salmon Creek Hospital Patient Name:_________________________ 2211 NE 139th St. Vancouver, WA 98686 Appointment Date:_____________________ (2nd floor, Surgery Patient Check-in) Arrival Time:__________________________ Peacehealth SW Medical Center 400 NE Mother Joseph Place Provider:______________________________ Vancouver, WA 98664 (5th Street entrance, Short Stay Unit) Please call our office at (360) 397-3805 with any questions Colonoscopy instructions using Miralax and Gatorade, with magnesium citrate. Bowel preparation (cleansing) is needed to perform a high-quality colonoscopy. Any stool remaining in the colon can hide important findings and result in the need to repeat the procedure. It is critical that you follow the instructions as directed. It is important that you follow the prep instructions as below, and not those located on the prep kit packaging. Prior to and during the procedure you will receive sedation (unless you request otherwise) through and IV. The sedation interferes with forming memories, so most patients do not even remember the procedure. Your physician will discuss any findings of your procedure with you in the recovery room. If biopsies are taken or polyps removed, you will receive a letter or MyChart message in 2-3 weeks detailing the final results and recommendations. If your results require a change in your current treatment plan, you may receive a phone call from the office. We make every effort to keep your appointment at the scheduled time, however unexpected delays may occur and your wait time prolonged. Please note that you may be asked to come in earlier than your scheduled time to accommodate changes that occur in the schedule.
    [Show full text]
  • Magnesium Citrate Preparation
    Division of Gastroenterology COLONOSCOPY PREPARATION INSTRUCTIONS Magnesium Citrate Preparation WHAT IS A COLONOSCOPY? • Your physician has recommended that you have a colonoscopy. This test is a visual examination of the lining of the large intestine. During the test, a colonoscope, which is a long, flexible instrument that has a light and a camera at the tip, will be passed through the rectum and around the colon. Your doctor will view the colonoscopy on a television screen and look for any abnormalities that may be present. • Colonoscopy usually is performed to evaluate and treat colon cancer, polyps, gastrointestinal bleeding and diarrhea. If necessary, biopsies (tiny tissue samples) may be taken painlessly during the examination and sent for laboratory analysis. Polyps (abnormal growths of tissue) also may be removed and bleeding areas may be identified and treated. PREPARING FOR A COLONOSCOPY Food and Drink • In order for your doctor to perform an adequate and safe examination, the colon must be clear. You will be given a laxative solution to drink prior to the examination. Follow the instructions carefully. • You should be on a modified diet the entire day before your colonoscopy. You may continue to have clear fluids the day of your procedure, up to three (3) hours prior to your examination. A clear fluid diet includes jello, coffee (please do not add milk), tea (please do not add milk), soft drinks, ices, clear soups, sports drinks such as Gatorade or Powerade and apple or white grape juice. Please avoid red or purple drinks, jello or popsicles for the 24 hours prior to the examination.
    [Show full text]
  • Liquid Cal/Mag/D
    PRODUCT DATA DOUGLAS LABORATORIES® 03/2013 1 Liquid Cal/Mag/D DESCRIPTION Liquid Cal/Mag/D by Douglas Laboratories provides the essential nutrients for bone health, which include calcium and magnesium in a 2:1 ratio and vitamin D3 in a great-tasting raspberry-flavored liquid, sweetened naturally with organic stevia and xylitol. FUNCTIONS The adult human body holds about 99% of all calcium and about 60% of magnesium in the skeleton. The remaining 1% of total body calcium and 40% of total body magnesium are found in the soft tissues and play important roles in such vital functions as nerve conduction, muscle contraction, energy metabolism, blood clotting, membrane permeability, and hormonal signaling. Blood calcium levels are carefully maintained within very narrow limits by the interplay of several hormones, including 1,25-dihydroxy-cholecalciferol, which control calcium absorption and excretion, as well as bone metabolism. The intracellular levels of magnesium are also very tightly regulated, since their alterations can have profound effects on cardiac and skeletal muscle physiology. Bone is constantly turning over, a continuous process of formation and resorption. In children and adolescents, the rate of formation of bone mineral predominates over the rate of resorption. In later life, resorption predominates over formation. Therefore, in normal aging, there is a gradual loss of bone. It is generally accepted that obtaining enough dietary calcium, magnesium, and vitamin D throughout life can significantly support optimal bone health. Vitamin D is a key regulatory hormone for calcium and bone metabolism. Adequate vitamin D status is essential for ensuring normal calcium absorption and maintenance of healthy calcium plasma levels.
    [Show full text]
  • Colonoscopy — Dulcolax®, Miralax® and Magnesium Citrate Prep
    EDUCATION Colonoscopy — Dulcolax®, MiraLAX® and Magnesium Citrate Prep Colonoscopy Your Procedure A colonoscopy is a procedure that lets your health care provider see your large intestine Location: ______________________________ (colon). This procedure is done using a long, Health care provider: ___________________ flexible tube (a “scope”) that passes into your rectum and through your colon. Date: _________________________________ The procedure takes about 15 to 30 minutes. Arrival time: ______________ a.m. / p.m. What You Will Need to Buy Procedure time: ___________ a.m. / p.m. Buy the following ingredients: Phone number: ________________________ — 10 milligrams (mg) Dulcolax® laxative Call the phone number above if you have (Do not use Dulcolax stool softener.) questions about your procedure. If you — MiraLAX® powder (238-gram bottle) need to cancel or reschedule, please call at least 24 hours before your procedure. — Gatorade®, Powerade® or water (64 ounces) — magnesium citrate (10-ounce bottle of — are pregnant liquid or 0.5-ounce package of powder). — have bleeding after surgery. Arrange to have someone drive you home The Week Before Your Procedure and stay with you for 24 hours after your You may receive a phone call from a nurse procedure. You will not be able to drive within 1 week of your procedure. after your procedure. You cannot take public transportation home alone. Tell your primary care provider if you: You will not be able to return to work after ® ® — take warfarin (Coumadin , Jantoven ) the procedure. or any type of blood thinners — take insulin or a diabetes pill. The Day Before Your Procedure He or she may want to change your dosages.
    [Show full text]
  • Magnesium Citrate Colonoscopy Prep
    Magnesium Citrate Colonoscopy Prep Instructions **READ INSTRUCTIONS CAREFULLY - AT LEAST 5 DAYS PRIOR TO PROCEDURE** In order for the physician to perform a colonoscopy, a bowel "cleanout" must be completed at home prior to your procedure. A bowel cleanout is a combination of a clear liquid diet and oral laxatives. All of the items can be obtained at your local pharmacy without a prescription. You will need to purchase the following: » Three 10 ounces bottles of Magnesium Citrate (liquid not pill form) » A small box of Dulcolax tablets (5 milligram tablets). NOT suppositories. » Clear liquids of your choice (see below for examples) » Baby wipes and/or Desitin or A&D ointment OPTIONAL. This helps prevent sore bottom. Do not wear ointment on bottom when you leave for procedure (obscures image) MANUFACTURER'S INSTRUCTIONS MAY DIFFER. PLEASE FOLLOW THE INSTRUCTIONS BELOW »**Contact Kayla, at physician's office, regarding any prescription blood thinners taken at home. »Discontinue any fiber supplements (Metamucil, Citrucel, Fibercon, etc.) at least five 5 days prior to procedure. »If you take narcotics, or suffer from chronic constipation, please take Miralax twice a day for five days prior to procedure. »Do not take any iron pills for 3 days prior to your colonoscopy. »It is best to eat lightly for a few days before your exam. It makes the cleanout easier and more effective. »Avoid whole wheat products and fibrous foods with skins, seeds, etc. DAY BEFORE COLONOSCOPY - Clear Liquids Only ** If you take narcotics at home, please take a bottle of Magnesium Citrate in the morning and then follow instructions below.
    [Show full text]
  • Cal/Mag/D Liquid Introduced 2012
    Product Information Sheet – February 2015 Cal/Mag/D liquid Introduced 2012 What Is It? Recommendations Cal/Mag/D liquid provides calcium and magnesium in a 2:1 ratio, Pure Encapsulations recommends 1 serving daily, with a meal, or as combined with vitamin D3 to promote calcium utilization and enhance directed by a health professional. healthy bone mineralization. This formula combines highly bioavailable forms of calcium, magnesium and vitamin D in a great-tasting raspberry Are There Any Potential Side Effects Or liquid for convenient dosing.* Precautions? High doses of magnesium can cause loose stools. If pregnant or Uses For Cal/Mag/D liquid lactating, or have a history of kidney stones, consult your physician Bone Health: Randomized, double-blind, placebo-controlled before taking this product. studies have reported statistically significant benefits of calcium supplementation for bone health. Magnesium, like calcium, is Are There Any Potential Drug Interactions? an essential bone matrix mineral that promotes healthy bone Calcium should be taken separately from certain antibiotics and metabolism. A trial involving 2,038 older individuals indicated that thyroid medications. Calcium and magnesium should be taken higher intakes of magnesium were positively associated with bone separately from bisphosphonate medications. Consult your physician mineralization for certain individuals. Vitamin D promotes intestinal for more information. calcium and phosphorous absorption and reduces urinary calcium loss, essential mechanisms for maintaining healthy calcium levels in Cal/Mag/D liquid the body and for healthy bone composition. A recent 7-year study involving 36,282 women indicated that combined supplementation of two teaspoons (10 ml / 0.33 fl oz) contain v calcium and vitamin D promoted healthy hip bones.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]